Treating neurodegenerative diseases with Rob Etherington, CEO of Clene Nanomedicine

Podcast | First in Human Episode #57 featuring Rob Etherington - CEO & President at CleneПодробнее

Bullish And Shorted CLNN Stock Points To A $5 Move And Higher!Подробнее

Rob Etherington, President & CEO, Clene Nanomedicine, On Treating Neurodegenerative DiseasesПодробнее

Clene Nanomedicine - Neurodegenerative DiseasesПодробнее

4th Annual ALS ONE Research Symposium - Presentation by Robert Glanzman, MD of Clene NanomedicineПодробнее

6th Annual ALS ONE Research Symposium: Day 2 Industry Speaker: Rob Etherington, Pres. & CEO at CleneПодробнее

Silicon Slopes: CleneПодробнее

Robert Glanzman, MD: Overview of CNM-Au8Подробнее

Developing New Treatments for Neurodegenerative DiseaseПодробнее

This Is the Sad Reality of ALS #shortsПодробнее

A Nano‐theranostic Approach for Neurodegenerative DiseasesПодробнее

Treating Neurodegenerative Diseases (2019)Подробнее

A new cure for neurodegenerative disease?Подробнее

Treatment of neurodegenerative disorders at EAN 2021Подробнее

2.7 Neurodegenerative DiseasesПодробнее